polio vaccine (Polymilex)

Coupled Information-Infection Dynamics Produce Information-Driven Shifts in Epidemic Regimes via Competing Vaccine Narratives.

Azizi Asma A, Kazanci Caner C, Guo Xiaohui X

Vaccine-related communication can be harnessed to curb infection; yet, in practice, it often undermines vaccine uptake and sustains transmission even when effective vaccines are available. Our goal is to understand how vaccine information dynamics may shape infection spread within a coupled information-infection modeling framework. We present a coupled information-infection modeling framework that links a standard SVIRS infection-spread model with an integrate-and-fire-inspired information-dissemination model. Vaccine-positive and vaccine-critical active groups disseminate competing information that shapes non-active/hesitant individuals' vaccine attitudes through direct peer influence, threshold-based acceptance, and persistence of engagement, while infection prevalence can feed back by amplifying caution. The evolving vaccine attitudes modulate vaccination uptake, and the model tracks the joint evolution of information dynamics and epidemic trajectories. Our analysis shows that, under the assumed coupling, information dynamics can shift the system among qualitatively distinct infection outcomes. In particular, reducing resistance to vaccine-positive information and sustaining vaccine-positive engagement can move the system toward lower-endemic regimes more reliably than changes focused only on weakening vaccine-critical engagement, for the parameter ranges considered here. These findings highlight the potential importance of information dynamics in epidemic modeling and suggest that sustained vaccine-positive engagement can be an important qualitative mechanism for reducing long-term infection burden.

Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations.

Lyth Johan J, Spreco Armin A, Hinkula Jorma J, Björneld Olle O et al.

Established determinants of health in the elderly help guide routines for indicated vaccine administration, while unmeasured frailty may limit vaccine access. We evaluate the performance of the 2024-2025 COVID-19 vaccine adapted to the Omicron JN.1 lineage in a Swedish population aged ≥65 years (N = 245 696). Vaccine effectiveness (VE) on COVID-19-related hospitalization and a negative control outcome (NCO; all-cause mortality) are assessed in various cohorts between October 1, 2024 to March 31, 2025. The VE was 75% (95% CI 70%-79%) overall, and 84% (95% CI 80%-87%) and 65% (95% CI 34%-82%) in individuals with and without vaccination with the prior updated COVID-19 vaccine in 2023-2024, respectively. The NCO in individuals exposed to the study vaccine in 2024-2025 was half of that seen in those not exposed to the vaccine (HR 0.43 [95% CI 0.40-0.45]). Removing individuals hospitalized with COVID-19 from this population did not change the difference in NCO (HR 0.43 [95% CI 0.41-0.46]). These findings suggest the presence of selection effects arising from under-provision of health services to elderly individuals with frailty. The healthy vaccinee effect should be considered in observational studies of the effectiveness of updated COVID-19 vaccines in elderly populations.

id.DRIVE: a public-private partnership for infectious disease surveillance, vaccine research, and pandemic preparedness in Europe and beyond.

Carmona Antonio A, Breugelmans J Gabrielle JG, Beutels Philippe P, Sánchez Brenda Marquina BM et al.

Durable clinical and immunologic response to an off-the-shelf EWSR1-FLI1 peptide vaccine in metastatic Ewing sarcoma.

Calukovic Branko B, Benzler Katrin K, Zelba Henning H, Seitz Christian C et al.

Ewing sarcoma is a rare, fusion-driven malignancy with poor prognosis in the metastatic setting, for which no established immunotherapeutic treatment is currently available. Fusion breakpoints are rational precision immunotherapy targets, yet clinical evidence of immunogenicity is scarce. We administered an off-the-shelf multi-peptide vaccine spanning the type 1 EWSR1-FLI1 breakpoint to a patient with high-burden metastatic Ewing sarcoma following multimodal therapy. Vaccinations were combined with GM-CSF and topical imiquimod. Longitudinal immune monitoring by in vitro peptide stimulation and intracellular cytokine staining revealed de novo polyfunctional CD4⁺ T-cell responses against all four fusion-derived peptides, first detectable by month 7 and persisting beyond two years. Treatment was well tolerated with only grade 1 local reactions. Durable disease stability was maintained for more than 26 months. These first-in-human data support the feasibility, safety, and immunogenicity of a fusion-derived peptide vaccine and warrant further evaluation of precision immunotherapy in sarcomas driven by recurrent gene fusions.